Invivyd Reports Q3 2026 Revenue of $15.4 Million and $33.5 Million Net Loss
Invivyd reported Q3 2026 revenue of $15.4M, up from $13.1M a year earlier, and a net loss of $33.5M. Cash reserves stood at $126.4M. The company expects interim data from its DECLARATION Phase 3 trial soon and announced positive results from the LIBERTY Phase 3 trial.
How this was made

The 30-second read
Why it matters
The earnings release combines a financial miss with encouraging clinical data, creating a nuanced trade signal.
Market read
Primary earnings disclosure for a micro‑cap biotech with material trial data; relevant for short‑term traders and sector analysts.
What to watch
Potential regulatory delays for accelerated approval and competition from mRNA vaccine makers.
Background
Invivyd is a clinical‑stage biotech developing monoclonal antibodies for COVID‑19 and other viral diseases.
Ticker impact
Invivyd filed its Q3 2026 earnings showing revenue of $15.4M, a widened net loss of $33.5M, and positive Phase 3 interim data for VYD2311.
modest upside potential from trial data, offset by pressure from expanding loss
The company reported a significant loss, which typically depresses price, but disclosed encouraging Phase 3 results that may attract investors seeking biotech upside.
Market effects
Positive trial data may lift peer biotech stocks focused on COVID‑19 therapeutics.
Limited to U.S. biotech sector; no broader regional effect.
Minimal global impact beyond niche biotech investors.
Counterpoint
The widening loss suggests cash burn may outpace growth, making the stock overvalued despite trial optimism.
Key entities
- companyInvivyd, Inc.
Biotech firm reporting Q3 2026 results and trial updates.
- personMarc Elia
Newly appointed CEO of Invivyd.
